Study of Remote and Local Hearing Tests to Monitor Hearing Loss in Adults with Head and Neck Squamous Cell Cancer Receiving Cisplatin andor Radiation

What this Trial Is About

Researchers are evaluating whether offering hearing tests audiometry closer to patients homes or remotely can increase participation in monitoring treatment-related hearing loss among patients with head and neck squamous cell cancer receiving cisplatin chemotherapy andor radiation. This study focuses on patients who may have difficulty returning for hearing tests due to advanced disease or long travel distances. Hearing loss caused by these treatments can significantly affect quality of life, and monitoring may help detect changes early to adjust treatments if needed. Participants are randomly assigned to one of two groups. Group I undergoes audiometry at the study center at baseline and at 3 and 12 months after treatment. Group II includes patients living more than 120 miles away or with stage IV disease these patients have audiometry at baseline at the study center and are offered either close to home audiometry or self-administered remote audiometry at 3 and 12 months. This approach aims to compare usual in-office testing with more accessible options. During the study, participants have audiometry tests at specified times before, during, and after treatment to measure hearing ability. Researchers will track the proportion of patients completing at least one post-treatment audiogram within 12 months and assess the incidence and severity of hearing loss. Additional interviews explore patient barriers to participation. The total study duration extends up to 12 months post-treatment, with monitoring continuing up to 30 days after study participation ends.

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation